Interaction of the sodium/glucose cotransporter (SGLT) 2 inhibitor canagliflozin with SGLT1 and SGLT2: Inhibition kinetics, sidedness of action, and transporter-associated incorporation accounting for its pharmacodynamic and pharmacokinetic featuress

Journal of Pharmacology and Experimental Therapeutics

Volumn 358, Issue 1, 2016, Pages 94-102

  Ohgaki, Ryuichi ^a   Wei, Ling ^a   Yamada, Kazunori ^b   Hara, Taiki ^b   Kuriyama, Chiaki ^b   Okuda, Suguru ^a   Ueta, Kiichiro ^b   Shiotani, Masaharu ^b   Nagamori, Shushi ^a   Kanai, Yoshikatsu ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA METHYLGLUCOSIDE; CANAGLIFLOZIN; CARBON 14; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; ANTIDIABETIC AGENT; SLC5A1 PROTEIN, HUMAN; SLC5A2 PROTEIN, HUMAN;

ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; IN VITRO STUDY; INHIBITION CONSTANT; INHIBITION KINETICS; KIDNEY PROXIMAL TUBULE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STABLE EXPRESSION; WHOLE CELL PATCH CLAMP; ACTION POTENTIAL; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING COMPETITION; CHO CELL LINE; CRICETULUS; DOSE RESPONSE; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; HUMAN; KINETICS; METABOLISM; PATCH CLAMP TECHNIQUE; SMALL INTESTINE;

ACTION POTENTIALS; ANIMALS; BINDING, COMPETITIVE; CANAGLIFLOZIN; CHO CELLS; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEK293 CELLS; HUMANS; HYPOGLYCEMIC AGENTS; INTESTINE, SMALL; KIDNEY TUBULES, PROXIMAL; KINETICS; PATCH-CLAMP TECHNIQUES; SODIUM-GLUCOSE TRANSPORTER 1; SODIUM-GLUCOSE TRANSPORTER 2; TRANSFECTION;

EID: 84976371974     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.116.232025     Document Type: Article

References (38)

1. Abdul-Ghani MA, DeFronzo RA, and Norton L (2013) Novel hypothesis to explainwhy SGLT2 inhibitors inhibit only 30-50%of filtered glucose load in humans. Diabetes 62:3324-3328.
2. Banerjee SK, McGaffin KR, Pastor-Soler NM, and Ahmad F (2009) SGLT1 is a novelcardiac glucose transporter that is perturbed in disease states. Cardiovasc Res 84:111-118.
3. Boyle LD and Wilding JP (2013) Emerging sodium/glucose co-transporter 2 inhibitorsfor type 2 diabetes. Expert Opin Emerg Drugs 18:375-391.
4. Cefalu WT (2014) Paradoxical insights into whole body metabolic adaptations followingSGLT2 inhibition. J Clin Invest 124:485-487.
5. Chen J, Williams S, Ho S, Loraine H, Hagan D, Whaley JM, and Feder JN (2010)Quantitative PCR tissue expression profiling of the human SGLT2 gene and relatedfamily members. Diabetes Ther 1:57-92.
6. Devineni D, Morrow L, Hompesch M, Skee D, Vandebosch A, Murphy J, Ways K, and Schwartz S (2012) Canagliflozin improves glycaemic control over 28 days insubjects with type 2 diabetes not optimally controlled on insulin. Diabetes ObesMetab 14:539-545.
7. Devineni D, Curtin CR, Polidori D, Gutierrez MJ, Murphy J, Rusch S, and RothenbergPL (2013) Pharmacokinetics and pharmacodynamics of canagliflozin, a sodiumglucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J ClinPharmacol 53:601-610.
8. Devineni D, Curtin CR, Marbury TC, Smith W, Vaccaro N, Wexler D, Vandebosch A, Rusch S, Stieltjes H, and Wajs E (2015) Effect of hepatic or renal impairment onthe pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Ther 37:610-628.
9. Elkinson S and Scott LJ (2013) Canagliflozin: first global approval. Drugs 73:979-988.
10. Eskandari S, Wright EM, and Loo DD (2005) Kinetics of the reverse mode of theNa1/glucose cotransporter. J Membr Biol 204:23-32.
11. Fujita Y and Inagaki N (2014) Renal sodium glucose cotransporter 2 inhibitors as anovel therapeutic approach to treatment of type 2 diabetes: clinical data andmechanism of action. J Diabetes Investig 5:265-275.
12. Ghezzi C and Wright EM (2012) Regulation of the human Na1-dependent glucosecotransporter hSGLT2. Am J Physiol Cell Physiol 303:C348-C354.
13. Ghezzi C, Hirayama BA, Gorraitz E, Loo DD, Liang Y, and Wright EM (2014) SGLT2inhibitors act from the extracellular surface of the cell membrane. Physiol Rep 2:e12058.
14. Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp DE, BakkerRA, Mark M, Klein T, and Eickelmann P (2012) Empagliflozin, a novel selectivesodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparisonwith other SGLT-2 inhibitors. Diabetes Obes Metab 14:83-90.
15. Hediger MA, Coady MJ, Ikeda TS, and Wright EM (1987) Expression cloning andcDNA sequencing of the Na1/glucose co-transporter. Nature 330:379-381.
16. Hummel CS, Lu C, Loo DD, Hirayama BA, Voss AA, and Wright EM (2011) Glucosetransport by human renal Na1/D-glucose cotransporters SGLT1 and SGLT2. Am JPhysiol Cell Physiol 300:C14-C21.
17. Iijima H, Kifuji T, Maruyama N, and Inagaki N (2015) Pharmacokinetics, pharmacodynamics, and safety of canagliflozin in Japanese patients with type 2 diabetesmellitus. Adv Ther 32:768-782.
18. Inagaki N, Kondo K, Yoshinari T, Ishii M, Sakai M, Kuki H, and Furihata K (2014)Pharmacokinetic and pharmacodynamic profiles of canagliflozin in Japanesepatients with type 2 diabetes mellitus and moderate renal impairment. Clin DrugInvestig 34:731-742.
19. Kanai Y, Lee WS, You G, Brown D, and Hediger MA (1994) The human kidney lowaffinity Na1/glucose cotransporter SGLT2. Delineation of the major renal reabsorptivemechanism for D-glucose. J Clin Invest 93:397-404.
20. Kinoshita S and Kondo K (2015) Evaluation of pharmacokinetic and pharmacodynamicinteractions of canagliflozin and teneligliptin in Japanese healthy malevolunteers. Expert Opin Drug Metab Toxicol 11:7-14.
21. Kuriyama C, Xu JZ, Lee SP, Qi J, Kimata H, Kakimoto T, Nakayama K, Watanabe Y, Taniuchi N, and Hikida K, et al. (2014) Analysis of the effect of canagliflozin onrenal glucose reabsorption and progression of hyperglycemia in zucker diabeticFatty rats. J Pharmacol Exp Ther 351:423-431.
22. Lavalle-González FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, and Meininger G (2013) Efficacy and safety of canagliflozin compared with placeboand sitagliptin in patients with type 2 diabetes on background metformin monotherapy:a randomised trial. Diabetologia 56:2582-2592.
23. Lee WS, Kanai Y, Wells RG, and Hediger MA (1994) The high affinity Na1/glucosecotransporter. Re-evaluation of function and distribution of expression. J BiolChem 269:12032-12039.
24. Liang Y, Arakawa K, Ueta K, Matsushita Y, Kuriyama C, Martin T, Du F, Liu Y, XuJ, and Conway B, et al. (2012) Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One 7:e30555.
25. Lu Y, Griffen SC, Boulton DW, and Leil TA (2014) Use of systems pharmacologymodeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renalglucose reabsorption in humans. Front Pharmacol 5:274.
26. Nomura S, Sakamaki S, Hongu M, Kawanishi E, Koga Y, Sakamoto T, Yamamoto Y, Ueta K, Kimata H, and Nakayama K, et al. (2010) Discovery of canagliflozin, anovel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter2 inhibitor for the treatment of type 2 diabetes mellitus. J Med Chem 53:6355-6360.
27. Oguma T, Kuriyama C, Nakayama K, Matsushita Y, Yoshida K, Kiuchi S, Ikenaga Y, Nakamaru Y, Hikida K, and Saito A, et al. (2015a) The effect of combined treatmentwith canagliflozin and teneligliptin on glucose intolerance in Zucker diabeticfatty rats. J Pharmacol Sci 127:456-461.
28. Oguma T, Nakayama K, Kuriyama C, Matsushita Y, Yoshida K, Hikida K, ObokataN, Tsuda-Tsukimoto M, Saito A, and Arakawa K, et al. (2015b) Intestinal sodiumglucose cotransporter 1 inhibition enhances glucagon-like peptide-1 secretion innormal and diabetic rodents. J Pharmacol Exp Ther 354:279-289.
29. Peene B and Benhalima K (2014) Sodium glucose transporter protein 2 inhibitors:focusing on the kidney to treat type 2 diabetes. Ther Adv Endocrinol Metab 5:124-136.
30. Polidori D, Sha S, Mudaliar S, Ciaraldi TP, Ghosh A, Vaccaro N, Farrell K, Rothenberg P, and Henry RR (2013) Canagliflozin lowers postprandial glucose andinsulin by delaying intestinal glucose absorption in addition to increasing urinaryglucose excretion: results of a randomized, placebo-controlled study. Diabetes Care36:2154-2161.
31. Ramratnam M, Sharma RK, D'Auria S, Lee SJ, Wang D, Huang XYN, and Ahmad F(2014) Transgenic knockdown of cardiac sodium/glucose cotransporter 1 (SGLT1)attenuates PRKAG2 cardiomyopathy, whereas transgenic overexpression of cardiacSGLT1 causes pathologic hypertrophy and dysfunction in mice. J Am HeartAssoc 3:e000899.
32. Sha S, Devineni D, Ghosh A, Polidori D, Chien S, Wexler D, Shalayda K, Demarest K, and Rothenberg P (2011) Canagliflozin, a novel inhibitor of sodium glucose cotransporter2, dose dependently reduces calculated renal threshold for glucoseexcretion and increases urinary glucose excretion in healthy subjects. DiabetesObes Metab 13:669-672.
33. Sha S, Polidori D, Farrell K, Ghosh A, Natarajan J, Vaccaro N, Pinheiro J, RothenbergP, and Plum-Mörschel L (2015) Pharmacodynamic differences between canagliflozinand dapagliflozin: results of a randomized, double-blind, crossover study. DiabetesObes Metab 17:188-197.
34. Silverman M (1974) The in vivo localization of high-affinity phlorizin receptors to thebrush border surface of the proximal tubule in dog kidney. Biochim Biophys Acta339:92-102.
35. Wiriyasermkul P, Nagamori S, Tominaga H, Oriuchi N, Kaira K, Nakao H, KitashojiT, Ohgaki R, Tanaka H, and Endou H, et al. (2012) Transport of 3-fluoro-La-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a causeof the tumor uptake in PET. J Nucl Med 53:1253-1261.
36. Wright EM, Loo DD, and Hirayama BA (2011) Biology of human sodium glucosetransporters. Physiol Rev 91:733-794.
37. You G, Lee WS, Barros EJG, Kanai Y, Huo TL, Khawaja S, Wells RG, NigamSK, and Hediger MA (1995) Molecular characteristics of Na(1)-coupled glucosetransporters in adult and embryonic rat kidney. J Biol Chem 270:29365-29371.
38. Zhou L, Cryan EV, D'Andrea MR, Belkowski S, Conway BR, and Demarest KT (2003)Human cardiomyocytes express high level of Na1/glucose cotransporter 1 (SGLT1). J Cell Biochem 90:339-346.